Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986207 alone or in combination in advanced solid tumors
NCT02913313Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label trial of BMS-986207 in solid tumor (advanced stage) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events up to 27 months, Number of Participants Who Died up to 27 months and 5 more. Started Nov 2016; status: completed.
02
Drugs
BMS-986207
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02913313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913313.